(12) **Translation of European patent specification**

(11) **NO/EP 3708178 B1**

NORWAY

(19) NO

(51) Int Cl.

A61K 38/07 (2006.01) ***A61P 27/02 (2006.01)*** ***A61P 27/12 (2006.01)***

Norwegian Industrial Property Office

(45)	Translation Published	2024.01.15
(80)	Date of The European Patent Office Publication of the Granted Patent	2023.10.04
(86)	European Application Nr.	20156769.0
(86)	European Filing Date	2010.08.23
(87)	The European Application's Publication Date	2020.09.16
(30)	Priority	2009.08.24, US, 23644009 P 2009.08.28, US, 23774509 P 2010.05.26, US, 34847010 P
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; SE; SI; SK; SM; TR
(73)	Proprietor	Stealth BioTherapeutics Inc., 140 Kendrick Street, Building C-West, Needham, MA 02494, USA
(72)	Inventor	TANG, Shibo, 54 South Xianlie Road, Guangzhou, Guangdong 510060, Kina LIU, Liping, 13560 Den Hollow Court, Manassas, VA Virginia 20112, USA LIANG, Xiaoling, 54 South Xianlie Road, Guangzhou, Guangdong, Kina
(74)	Agent or Attorney	Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike

(54) Title **PEPTIDE FOR USE IN PREVENTING OR TREATING MACULAR DEGENERATION**

(56) References Cited:

WO-A1-2011/091357, US-A1- 2006 084 606, WO-A2-2009/108695,

BRENNAN L A ET AL: "Mitochondrial function and redox control in the aging eye: Role of MsrA and other repair systems in cataract and macular degenerations", EXPERIMENTAL EYE RESEARCH, ACADEMIC PRESS LTD, LONDON, vol. 88, no. 2, 2 February 2009 (2009-02-02), pages 195-203, XP026072626, ISSN: 0014-4835, DOI: 10.1016/J.EXER.2008.05.018 [retrieved on 2008-06-07]

YOUSIF LEMA F ET AL: "Targeting Mitochondria with Organelle-Specific Compounds: Strategies and Applications", CHEMBIOCHEM - A EUROPEAN JOURNAL OF CHEMICAL BIOLOGY, WILEY VCH, WEINHEIM, DE, vol. 10, no. 12, 17 August 2009 (2009-08-17), pages 1939-1950, XP009167550, ISSN: 1439-4227 [retrieved on 2009-07-27]

YANG LICHUAN ET AL: "Mitochondria Targeted Peptides Protect Against 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridi ne Neurotoxicity", ANTIOXIDANTS AND REDOX SIGNALING, MARY ANN LIEBERT, LARCHMONT, NY, US, vol. 11, no. 9, 1 September 2009 (2009-09-01), pages 2095-2104, XP009167548, ISSN: 1523-0864

ALAM N M ET AL: "Reducing mitochondrial oxidative stress to treat diabetes- and age-related visual decline", ABSTRACTS OF THE ANNUAL MEETING OF THE SOCIETY FOR NEUROSCIENCE, SOCIETY FOR NEUROSCIENCE, WASHINGTON, DC, US, vol. 41, 1 November 2011 (2011-11-01), XP009167565, ISSN: 0190-5295

LI J ET AL: "Mitochondria-targeted antioxidant peptide SS31 attenuates high glucose-induced injury on human retinal endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 404, no. 1, 7 January 2011 (2011-01-07), pages 349-356, XP027587037, ISSN: 0006-291X, DOI: 10.1016/J.BBRC.2010.11.122 [retrieved on 2011-01-06]
CHATURVEDI RAJNISH K ET AL: "Mitochondrial approaches for neuroprotection.", ANNALS OF THE NEW YORK ACADEMY OF SCIENCES DEC 2008, vol. 1147, December 2008 (2008-12), pages 395-412, XP009167547, ISSN: 1749-6632
X. Liang, F. Chen, H. Zhou, C. Yang, G. Sun, Q. Gao, Y. Luo,: "SS31 Protects Human RPE Cells From Oxidative Damage and Reduce Laser-Induced Choroidal Neovascularization", , 3 March 2010 (2010-03-03), XP009167611, Retrieved from the Internet: URL:http://www.abstractsonline.com/plan/Vi ewAbstract.aspx?mID=2511&sKey=30ba9e7c-8ff 2-4a2d-9b34-8bd3ce86ee29&cKey=bb556ca3-13a 0-40dd-8b09-f328d94cdeb2&mKey={1EA90E66-C5 48-49E0-9F05-30DA7938D511} [retrieved on 2013-02-28]
JARRETT S G ET AL: "Mitochondrial DNA damage and its potential role in retinal degeneration", PROGRESS IN RETINAL AND EYE RESEARCH, OXFORD, GB, vol. 27, no. 6, 1 November 2008 (2008-11-01), pages 596-607, XP025670749, ISSN: 1350-9462, DOI: 10.1016/J.PRETEYERES.2008.09.001 [retrieved on 2008-09-23]

Patentkrav

1. Peptid representert av formelen D-Arg-2'6'-Dmt-Lys-Phe-NH_2 eller Phe-D-Arg-Phe-Lys-NH_2, for anvendelse i behandling eller forebygging av en oftalmisk tilstand, hvori den oftalmiske tilstanden er makuladegenerasjon.

2. Peptidet for anvendelse ifølge krav 1, hvori peptidet er D-Arg-2'6'-Dmt-Lys-Phe-NH_2.

3. Peptidet for anvendelse ifølge krav 1, hvori peptidet er Phe-D-Arg-Phe-Lys-NH_2.

4. Peptidet for anvendelse ifølge krav 1, hvori individet er et menneske.

5. Peptidet for anvendelse ifølge krav 1, hvori peptidet er formulert for å administreres intraokulært, iontoforetisk, oralt, topisk, systemisk, intravenøst, subkutant eller intramuskulært.

6. Peptidet for anvendelse ifølge krav 1, hvori peptidet er formulert for å administreres med et andre aktivt middel.

7. Peptidet for anvendelse ifølge krav 6, hvori det andre aktive midlet velges fra gruppen som består av: en antioksidant, en metallkomplekser, et ant-inflammatorisk legemiddel, et antibiotikum og et antihistamin.

8. Peptidet for anvendelse ifølge krav 7, hvori antioksidanten er vitamin A, vitamin C, vitamin E, lykopen, selen, α-liponsyre, koenzym Q, glutation eller et karotenoid.

9. Peptidet for anvendelse ifølge krav 6, hvori det andre aktive midlet velges fra gruppen som består av: aceclidin, acetazolamid, anecortave, apraklonidin, atropin, azapentacen, azelastin, bacitracin, befunolol, betametason, betaksolol, bimatoprost, brimonidin, brinzolamid, karbakol, karteolol, celekoksib, kloramfenikol, klortetrasyklin, ciprofloksacin, kromoglykat, kromolyn, syklopentolat, syklosporin, dapiprazol, demekarium, deksametason, diklofenak, diklorfenamid, dipivefrin, dorzolamid, ekkotiofat, emedastin, epinastin, epinefrin, erytromycin, etokszolamid, eukatropin, fludrokortison, fluormetolon, flurbiprofen, fomivirsen, framycetin, ganciklovir, gatifloksacin, gentamycin, homatropin, hydrokortison, idoksuridin, indometacin, isoflurofat, ketorolac, ketotifen, latanoprost, levobetaksolol, levobunolol, levokabastin, levofloksacin, lodoksamid, loteprednol, medryson, metazolamid, metipranolol, moksifloksacin, nafazolin, natamycin, nedokromil, neomycin, norfloksacin, ofloksacin, olopatadin, oksymetazolin, pemirolast, pegaptanib, fenylefrin, fysostigmin, pilokarpin, pindolol, pirenoksin, polymyksin B, prednisolon, proparakain, ranibizumab, rimeksolon, skopolamin, sezolamid, skvalamin, sulfacetamid, suprofen, tetrakain, tetrasyklin, tetrahydrozolin, tetryzolin, timolol, tobramycin, travoprost, triamcinolon, trifluormetazolamid, trifluridin, trimetoprim, tropikamid, unoproston, vidarbin, xylometazolin, farmasøytisk akseptable salter derav, og kombinasjoner derav.